A Phase 2 interventional study of Afimetoran and Placebo in Systemic Lupus Erythematosus, sponsored by Beeline Medicines Corporation. Active, not recruiting at 147 sites in 19 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Beeline Medicines Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 96th largest by enrollment of the 407 interventional ones that give a count, is one of 20 that started in 2021, is one of 120 in phase 2, reaches primary completion later than 10 of the 125 other live ones, and was the 325th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Fate Therapeutics · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
477 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 130 · Phase 2 151 · Phase 3 75 · Phase 4 17
First in 1986; this study’s year is marked. 20 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 248 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 70 across the 407 interventional studies, 223 across the 67 observational. Of the 309 that completed or were terminated, 147 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
264 of 477 have an industry lead sponsor. The 10 most frequent:
Beeline Medicines Corporation is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Beeline Medicines Corporation has 1 study filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
33 of the studies in Lupus Erythematosus, Systemic with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
Add all 33 to your calendar (.ics) → With an account.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Drug: Afimetoran
Drug: Afimetoran
Drug: Afimetoran
Other: Placebo
Specified dose on specified days
Also known as: BMS-986256
Specified dose on specified days
Proportion of participants that achieve an SLE (Systemic Lupus Erythematosus) Responder Index (4) (SRI(4)) response at Week 48
Time frame: Up to 48 Weeks
Proportion of participants that achieve a British Isles Lupus Assessment Group (BILAG)-based Combine Lupus Assessment (BICLA) response at Week 24 and Week 48
Time frame: Up to 48 Weeks
Proportion of participants who achieve an SRI(4) response at Week 24
Time frame: Up to 24 Weeks
Proportion of participants who achieve a Lupus Low Disease Activity State (LLDAS) response at Week 24 and Week 48
Time frame: Up to 48 Weeks
Proportion of participants with a Cutaneous Lupus Erythematosus Disease Area and Severity Index; Activity (CLASI-A) score ≥ 10 at baseline who achieve a decrease of ≥ 50% from baseline CLASI-A score (CLASI-50) response at Week 24 and Week 48
Time frame: Up to 48 Weeks
Proportion of participants with 6 or more swollen joints and 6 or more tender joints at baseline who achieve a ≥ 50% reduction from baseline in both swollen and tender joints at Week 24 and Week 48
Time frame: Up to 48 Weeks
Mean change from baseline in swollen joint count using the 28-joint count at Week 24 and Week 48 in participants with ≥ 2 swollen joints at baseline
Time frame: Up to 48 Weeks
Mean change from baseline in tender joint count at Week 24 and Week 48 using the 28- joint count in participants with ≥ 2 tender joints at baseline
Time frame: Up to 48 Weeks
Change from baseline in PGA score of disease activity at Week 24 and Week 48
PGA = Physician Global Assessment of disease activity (score of "0" indicating no disease activity and higher scores indicating higher disease activity)
Time frame: Up to 48 Weeks
Proportion of participants who achieve CS reduction or maintenance to ≤ 7.5 mg per day at Week 48
Time frame: Up to 48 Weeks
Change in participant reported disease activity from baseline to Week 24 and Week 48 according to the 36-item Short Form Health Questionnaire (SF-36)
The SF-36 was designed as an indicator of health status in population surveys, and health policy evaluations, and for use as an outcome measure in clinical practice and research. Scores for each domain range from 0 to 100, with high scores indicating a better health status.
Time frame: Up to 48 Weeks
Number of participants with Adverse Events (AEs)
Time frame: Up to 100 Weeks
Number of participants with Serious Adverse Events (SAEs)
Time frame: Up to 100 Weeks
Number of participants with clinical laboratory abnormalities
Time frame: Up to 100 Weeks
Number of participants with physical examination abnormalities
Time frame: Up to 100 Weeks
Number of participants with vital sign abnormalities
Time frame: Up to 100 Weeks
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 52 Weeks
Showing the first 100 of 147 sites across 19 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Oct 2021 to primary completion in Jun 2026, 56 months.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 56 months is above that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afimetoran
Lupus Erythematosus, Systemic →
Beeline Medicines Corporation